Literature DB >> 16641477

Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?

Andre C Kalil, Susan Puumala, Julie Stoner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641477      PMCID： PMC1472210          DOI： 10.1128/AAC.50.5.1910-1911.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

Review 1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

2.  Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics.

Authors:  Dennis L Stevens; Randi J Wallace; Stephanie M Hamilton; Amy E Bryant
Journal:  Clin Infect Dis       Date:  2006-03-01       Impact factor: 9.079

3.  Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Authors:  George Sakoulas; George M Eliopoulos; Vance G Fowler; Robert C Moellering; Richard P Novick; Natalie Lucindo; Michael R Yeaman; Arnold S Bayer
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.

Authors:  John Weigelt; Kamal Itani; Dennis Stevens; William Lau; Matthew Dryden; Charles Knirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

Authors:  J Fagon; H Patrick; D W Haas; A Torres; C Gibert; W G Cheadle; R E Falcone; J D Anholm; F Paganin; T C Fabian; F Lilienthal
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

6.  Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001.

Authors:  Scott K Fridkin; Jeff Hageman; Linda K McDougal; Jasmine Mohammed; William R Jarvis; Trish M Perl; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079
  6 in total
  2 in total

1.  Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.

Authors:  Aisling R Caffrey; Brian J Quilliam; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

2.  Current and novel antibiotics against resistant Gram-positive bacteria.

Authors:  Federico Perez; Robert A Salata; Robert A Bonomo
Journal:  Infect Drug Resist       Date:  2008-09-09       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.